Zeo ScientifiX, Inc.

ZEOX

US68621D2062

Pharmaceuticals

Delayed OTC Markets Other stock markets 01:13:18 2024-04-29 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-3.85%		-14.62%	+22.55%

Mar. 18	Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
Mar. 05	Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL	CI

Organicell Regenerative Medicine, Inc. Announces Termination of Dr. Maria Ines Mitrani as its Chief Scientific Officer

May 01, 2023 at 04:05 pm EDT

On April 28, 2023, Organicell terminated Dr. Maria Ines Mitrani as its Chief Scientific Officer and contemporaneously terminated her employment agreement with the Company.

Latest news about Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 18	CI
Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL	Mar. 05	CI
Organicell Regenerative Medicine, Inc. will Change its Name to Zeo ScientifiX, Inc	Feb. 20	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Jan. 29	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-14	CI
Organicell Regenerative Medicine, Inc. announced a financing transaction	23-08-14	CI
An unknown buyer acquired Laboratory Facility Located in Basalt, Colorado from Organicell Regenerative Medicine, Inc. for $1.25 million.	23-08-08	CI
Organicell Regenerative Medicine, Inc. Reports Interim Results of Phase 1/2A Research Program	23-07-26	CI
Organicell Regenerative Medicine, Inc. Announces Resignation of Maria Ines Mitrani as Director	23-07-11	CI
Organicell Welcomes Howard Golub as Its New EVP/CSO	23-06-29	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-16	CI
Organicell Regenerative Medicine, Inc. Announces Executive Changes	23-06-06	CI
Organicell Regenerative Medicine, Inc. Announces Management Changes	23-06-06	CI
Organicell Regenerative Medicine, Inc. Terminates Albert Mitrani as Its Executive Vice President of Sales	23-05-15	CI
Organicell Regenerative Medicine, Inc. Announces Termination of Dr. Maria Ines Mitrani as its Chief Scientific Officer	23-05-01	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-17	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-17	CI
Organicell Regenerative Medicine, Inc. announced that it has received $0.5194 million in funding from AJB Capital Investments LLC	23-03-05	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-14	CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-14	CI
Organicell Regenerative Medicine, Inc. Auditor Raises 'Going Concern' Doubt	23-02-13	CI
John Chiste Resigns as Member of Organicell Regenerative Medicine's Board of Directors	22-12-23	CI
Organicell Regenerative Medicine, Inc. Accepts the Resignation of Mr. Matthew Sinnreich as President of the Company and as A Member of the Companyâ€™S Board of Directors	22-12-01	CI
Organicell Regenerative Medicine, Inc. Announces Management Changes	22-12-01	CI
Organicell Regenerative Medicine, Inc. Announces Resignation of Ryan Likes as Chief Operating Officer	22-11-25	CI

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Companyâs product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
ZEO SCIENTIFIX, INC.	+22.55%	7.96M
MCKESSON CORPORATION	+16.08%	71.39B
CARDINAL HEALTH, INC.	+1.83%	25.1B
SINOPHARM GROUP CO. LTD.	-1.22%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.95%	8.19B
HUADONG MEDICINE CO., LTD	-20.48%	7.91B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+15.26%	4.31B
EBOS GROUP LIMITED	-1.24%	3.93B
GALENICA AG	-3.02%	3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.10%	3.64B

Pharmaceuticals Wholesale

Zeo ScientifiX, Inc.

Equities

ZEOX

US68621D2062

Pharmaceuticals

Organicell Regenerative Medicine, Inc. Announces Termination of Dr. Maria Ines Mitrani as its Chief Scientific Officer

Latest news about Zeo ScientifiX, Inc.

Chart Zeo ScientifiX, Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale